Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: plhky3465 who wrote (50173)	2/8/2019 4:31:14 PM
From: allatwwk	Read Replies (1) of 63287

Phil, for the record, I'd be disappointed with a $25-ish buyout price. Get close to $50 and my vote becomes a yes. 132 in the right hands is worth it, probably more. The drug itself didn't miss, but the mfg did -- other companies have the expertise to get this right. Alas, I think the problem is temporary. IMMU will outsource all its mfg by 2021, with a lab scale operation for research/testing needs. On a slightly different track, I've thought of this mgmt team by using a metaphor from hockey. You go where the puck is headed rather than where it is. To me, this mgmt team is well-suited to run a mid-tier biopharma, which is where IMMU is headed. I never had a sense that getting from a productive science lab to functional internal manufacturing was a management strength. I did think they'd be good enough to get this done for AA, but apparently not.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next